Pharmaceutical painkillers vs legal cannabis – evidence, regulation and advice
Chronic pain affects millions of people in the UK and many resort to strong pharmaceutical painkillers such as codeine, tramadol or morphine. With growing interest in cannabis‑based products, patients often ask whether cannabinoids offer safer or more effective alternatives. This article reviews the evidence and explains how UK law and health guidance approach these treatments.
How pharmaceutical opioids work
Opioid medicines work by binding to μ‑opioid receptors in the brain and spinal cord, reducing the perception of pain. Strong opioids like morphine and oxycodone are often prescribed for acute postoperative pain or palliative care, while moderate opioids such as codeine or tramadol are used for injury‑related pain. Over time the body becomes tolerant; higher doses are required to achieve the same effect (known as tolerance), and patients can become physically dependent.
Long‑term use of morphine, codeine or tramadol can lead to increased sensitivity to pain (opioid‑induced hyperalgesia) and people may experience withdrawal symptoms if they stop suddenly. Side‑effects include constipation, drowsiness, dizziness, nausea and serious risks such as respiratory depression or seizures. Dependence and addiction are significant concerns, particularly when opioids are used for chronic non‑cancer pain, and UK guidelines now discourage long‑term opioid prescribing for chronic pain. The Scottish Intercollegiate Guidelines Network (SIGN) 2025 chronic pain guideline recommends limiting opioids to short‑term (≤3 months) use after other therapies have been tried, with close monitoring and specialist advice for high doses.
What are cannabis‑based products?
Cannabis plants contain hundreds of compounds; the most notable are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is psychoactive and gives the “high” associated with recreational cannabis. CBD is not intoxicating and has been marketed in oils, capsules, creams and edibles. UK law classifies cannabis and THC‑containing products as Class B drugs, making possession or supply illegal unless prescribed. CBD sold as a supplement is legal if it contains negligible THC, but the Food Standards Agency (FSA) warns that many products are unregulated, may contain undisclosed THC and should not be used by pregnant or breastfeeding women or people on medications.
Medical cannabis (cannabis‑based products for medicinal use, or CBPMs) were legalised in the UK in 2018, but the NHS only prescribes them for a very limited number of conditions: severe treatment‑resistant epilepsy, chemotherapy‑induced nausea and vomiting, and spasticity in multiple sclerosis. Long‑term pain is not an approved indication because robust evidence is lacking. Private clinics can prescribe CBPMs for chronic pain, but these products are often unlicensed and contain varying ratios of THC and CBD; costs are high and long‑term safety data are limited.
Evidence on cannabinoids for pain
Recent systematic reviews highlight the uncertainty around cannabinoids for chronic pain. A 2025 update of the Cochrane review assessed 21 randomised trials of THC‑dominant, THC/CBD‑balanced and CBD‑dominant products for neuropathic pain. The review concluded that it is unclear whether THC‑dominant medicines provide meaningful pain relief compared with placebo, and they may increase nervous‑system side‑effects such as dizziness. For THC/CBD‑balanced products, there was no clear evidence of significant pain relief, though they may lead some patients to rate their condition as improved, but also increased withdrawal due to adverse events. Evidence for CBD‑dominant products was very limited. The review rated the certainty of evidence as low to very low and urged better‑designed studies. An earlier Nature meta‑analysis of cannabis and opioids found pre‑clinical synergy but reported that high‑quality clinical trials did not demonstrate an opioid‑sparing effect or improved pain control; observational studies were of low quality and prone to bias.
UK guidelines reflect this uncertainty. The National Institute for Health and Care Excellence (NICE) guideline NG193 (2021) advises against starting cannabis‑based medicinal products for chronic primary pain and against initiating opioids, noting lack of efficacy and risk of dependence. The SIGN 2025 guideline similarly states that cannabis‑based products should not be used outside clinical trials for chronic pain. NHS England’s 2023 guidance reiterates that there is insufficient evidence for CBPMs in pain and warns of potential harms.
Comparing risks and benefits
| Consideration | Pharmaceutical opioids | Legal cannabinoids |
|---|---|---|
| Evidence of pain relief | Strong short‑term analgesia; limited or no benefit for chronic non‑cancer pain. | No clear evidence of clinically significant pain relief in chronic neuropathic pain. |
| Side‑effects | Common: nausea, constipation, dizziness, drowsiness; serious: respiratory depression, overdose. | Low THC: has no psychoactive effects, dizziness, confusion; CBD: diarrhoea, fatigue; unregulated products may contain contaminants. |
| Dependence/addiction | High risk; tolerance and dependence common. | Low THC‑containing products will not cause dependence and withdrawal; CBD alone appears non‑addictive but unproven. |
| Regulation and access in the UK | Controlled drugs; available via prescription for acute or cancer pain; guidelines restrict long‑term use. | CBPMs rarely prescribed on the NHS; private prescriptions available but unlicensed. CBD supplements legal but unregulated. |
| Cost and availability | Typically covered by NHS prescription; low cost. | Private CBPM prescriptions cost hundreds of pounds per month; supplements vary widely. |
Should people switch from opioids to cannabinoids?
Given the current evidence, cannabis‑based products cannot be recommended as replacements for prescription opioids. Opioids remain effective for short‑term acute pain and palliative care, while cannabinoids have not demonstrated consistent benefits in randomised trials. Both classes carry risks: opioids are associated with dependence and potentially fatal overdose, whereas THC‑containing products carry psychoactive and psychiatric risks and may also lead to dependence. CBD products may seem safer, but their long‑term effects and purity are uncertain, and they can interact with medications.
People living with chronic pain should discuss any interest in cannabinoids with a healthcare professional. In the UK, only specialists with training can prescribe CBPMs, and patients must have exhausted conventional options. Non‑pharmacological approaches—such as physiotherapy, cognitive‑behavioural therapy, pacing, and lifestyle changes—are emphasised as first‑line strategies for chronic pain.
FAQ
Can I buy CBD products from the high street and stop taking my painkillers?
UK law allows the sale of CBD food supplements that contain less than 1 mg THC per container, but the FSA warns that these products are not medicines, may vary widely in quality and should not be used by pregnant or breastfeeding women. Never stop prescription painkillers abruptly, speak to your GP about tapering.
Is cannabis legal for pain in the UK?
Cannabis remains a Class B controlled drug. Only a small number of patients receive NHS prescriptions for cannabis‑based medicines for specific conditions like severe epilepsy. Chronic pain is not an approved indication. Legal cannabinoids are however available.
Do cannabis products help reduce opioid doses?
Pre‑clinical studies suggest cannabinoids could enhance opioid analgesia, but clinical trials have not shown a consistent opioid‑sparing effect. More research is needed.
Are there any legal, plant‑based alternatives for pain?
Over‑the‑counter options such as NSAIDs (ibuprofen, naproxen) and paracetamol may help with acute pain but have their own risks. Some people use legal cannabinoids or complementary therapies (acupuncture, yoga, mindfulness); evidence varies. Always consult a healthcare professional.
Where can I find more information?
For official advice, visit the NHS page on medical cannabis and the NICE chronic pain guideline. These UK sites provide up‑to‑date information on regulations and treatment options.
Can CBD replace tramadol or morphine for pain relief in the UK?
Current UK medical evidence does not support replacing prescription opioids with CBD without medical supervision. Opioids are still used for acute and cancer pain, while cannabis-based products lack consistent high-quality evidence for chronic pain relief.
Is medical cannabis prescribed for chronic pain in the UK?
Medical cannabis can be prescribed privately, but NHS prescriptions are extremely limited and chronic pain is not routinely approved.
Is CBD safer than codeine?
CBD does not cause respiratory depression like opioids, but it can interact with medications and is not a proven substitute for prescription painkillers.
Are opioids more addictive than cannabis?
Prescription opioids carry a high risk of dependence and tolerance. THC-containing cannabis products can also cause dependence, though typically at lower rates.
Exploring Legal Cannabinoid Options?
If you’re researching alternatives to strong pharmaceutical painkillers, it’s important to understand the UK legal framework. At Weed Supermarket, we supply lab-tested legal cannabinoid products compliant with UK regulations.
Always consult a healthcare professional before changing medication.
